Market revenue in 2023 | USD 8.3 million |
Market revenue in 2030 | USD 28.5 million |
Growth rate | 19.4% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.24% in 2023. Horizon Databook has segmented the Brazil plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The primary factors that can be attributed to this share are growing use of plasmid DNA for creating vaccines & medications for various diseases & gene therapies, which is also witnessing rapid growth. Furthermore, rising incidence & prevalence of cancer, growing geriatric population, and rapid growth of the biopharmaceutical industry are all factors contributing to growth of the market in the country.
The elderly population of Brazil has significantly grown during the past few decades. According to a blog by The Borgen Project, the population of those older than 60 has increased from 5.0% of the total population in the 1970s to 15.0% by 2018 and is expected to reach more than 25.0% by 2050.
Brazil is expected to have the fourth-largest elderly population in the world by 2050 after India, China, and the U.S. Moreover, biopharmaceuticals are gaining share in the pharmaceuticals market, according to an article by Brazilian Journal of Pharmaceutical Sciences on “The production of biopharmaceuticals in Brazil.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account